PharmAthene soars after court denies SIGA's motion Print E-mail
By Staff and Wire Reports   
Wednesday, 24 November 2010 19:48
Below is a look at some of the headlines for companies that made news in the healthcare sector on November 24, 2010.

PharmAthene, Inc. (NYSE Amex: PIP) announced Wednesday that the Delaware Court of Chancery has issued a ruling denying in full SIGA Technologies' (Nasdaq:SIGA) motion for partial summary judgment in PharmAthene's breach of contract lawsuit against SIGA. The trial in PharmAthene's complaint in this case is set to commence on January 3, 2011.

The dispute is the result of a failed merger between the two companies in 2006 and the subsequent battle over the development and marketing rights to the anti-viral ST-246. On October 13th of this year SIGA was awarded a potential $2.8 billion BARDA contract to deliver 1.7 million courses of the smallpox anitdote for the Strategic National Stockpile.

Shares of PharmAthene surged more than 18% or 60 cents to $3.83. SIGA closed at $12.99, up 39 cents on the day.

Arena Pharmaceuticals, Inc. (Nasdaq:ARNA) announced today that the company is scheduled to present at the Piper Jaffray 22nd Annual Health Care Conference on December 1, 2010, at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) at the New York Palace Hotel in New York City.

Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced Paul F. Truex, Anthera's President and Chief Executive Officer, will present at the 22nd Annual Piper Jaffray Health Care Conference in New York, NY on Tuesday, November 30, 2010 at approximately 11:00 am Eastern Time.

China Cord Blood Corporation (NYSE:CO) China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced unaudited financial results for the second quarter and first half of fiscal 2011 ended September 30, 2010.

D. Medical Industries Ltd. (NASDAQ:DMED) (TASE:DMDC) a medical device company engaged through its subsidiaries in the research, development, manufacture and sale of innovative products for diabetes treatment and drug delivery, today announced financial results for the three and nine months ended September 30, 2010.

ERT (Nasdaq:ERES) announced today that Dr. Michael J. McKelvey, the Company's President and CEO, is scheduled to present at Piper Jaffray's 22nd Annual Health Care Conference at 12:00 PM EST on December 1, 2010 in New York City, New York.

NeurogesX, Inc. (Nasdaq:NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced that the board of directors has voted to expand the size of the Company's board from six to seven members with the appointment of Steven Nelson, effective November 17, 2010.

Omeros Corporation (Nasdaq:OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 22nd Annual Piper Jaffray Health Care Conference on November 30, 2010 at 3:00 p.m. Eastern time in New York City.

TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced radiation therapy solutions for the treatment of cancer and other diseases, today announced that President and CEO Fred Robertson, M.D., will participate in two upcoming investment community conferences.

Weikang Bio-Technology Group Co., Inc. (OTC Bulletin Board:WKBT) a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritional products in the People's Republic of China, today announced it will present at PHARMCHINA'S 64th National Medicine Trade Conference to be held in Nanchang from December 9 -11, 2010.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus